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Abstract Meningitis caused by enteric flora is a known
complication of strongyloidiasis, and human T-lympho-
tropic virus-1 (HTLV-1) predisposes individuals to severe
strongyloidiasis. We reviewed the clinical features of
bacterial meningitis associated with strongyloidiasis seen
at a single center in subtropical Japan, in an area endemic
for both strongyloidiasis and HTLV-1. We found 33 epi-
sodes in 21 patients between 1990 and 2010. The results
were remarkable for the high incidence of meningitis due
to Gram-positive cocci (27.3 %), especially Streptococcus
bovis, and culture-negative cases (42.4 %). Given the high
incidence of Gram-positive meningitis, a modified
approach to corticosteroid use would be advisable in areas
where strongyloidiasis is endemic, due to the potentially
adverse consequences of glucocorticoid therapy.
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Introduction
Strongyloides stercoralis (S. stercoralis) is a nematode
helminth that causes strongyloidiasis. It affects nearly 100
million people in tropical and subtropical areas of Europe,
Africa, Latin America, and Asia. Most cases are chronic
and asymptomatic, but severe infections such as hyperin-
fection syndrome (HIS) and disseminated strongyloidiasis
(DS) occur when cellular immunity is compromised. In
HIS (1.5–2.5 % of cases), manifestations are confined to
the respiratory and gastrointestinal (GI) systems. DS,
infection with multiple organ involvement other than the
respiratory and GI systems such as the brain or the skin,
may have a mortality of up to 87 % [1].
Bacterial meningitis caused by enteric flora is a poten-
tially fatal complication of DS/HIS. Localized strongyloi-
diasis, as well as DS/HIS, can predispose individuals to
bacterial meningitis with enteric organisms such as Kleb-
siella pneumoniae (K. pneumoniae), Escherichia coli
(E. coli), and Enterococcus spp. in the absence of evidence
for strongyloidiasis outside the GI tract [2, 3].
Human T-lymphotropic virus-1 (HTLV-1) is a retrovirus
that infects 10–20 million people worldwide. The virus is
highly prevalent in Japan, sub-Saharan Africa, the Carib-
bean, and South America. Southern Japan is the area with
the highest HTLV-1 prevalence, with over 10 % of the
general population being infected [4]. HTLV-1 can be
transmitted from mother to child, through sexual contact,
and through contaminated blood products. Most cases
are asymptomatic, but adult T cell leukemia/lymphoma
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(ATLL) and HTLV-1-associated myelopathy/tropical
spastic paresis may occur.
Co-infection with S. stercoralis and HTLV-1 predisposes
individuals to DS/HIS, possibly because HTLV-1 interferes
with Th2 cell responses to S. stercoralis, including eosino-
phil activation and production of interleukins and IgE [5].
Glucocorticoids, malignancies, human immunodeficiency
virus (HIV), organ or marrow transplantation, hypogam-
maglobulinemia, leprosy, tuberculosis, and malnutrition also
increase the risk [1]. This report delineates the clinical fea-
tures of bacterial meningitis associated with strongyloidiasis
seen at a single center in subtropical Japan, in an area
endemic for both strongyloidiasis and HTLV-1.
Methods
Cases with both bacterial meningitis and strongyloidiasis
were extracted from a review of the discharge diagnoses
for all hospitalizations at Okinawa Chubu Hospital
between January 1990 and May 2010. This large general
hospital serves a subtropical area. The prevalence of
strongyloidiasis and HTLV-1 in this area is reportedly 6.3
and 14 %, respectively [5]. About 39,000 patients visit the
emergency department and nearly 14,000 patients are
hospitalized per year.
After review, we included cases that met the following
inclusion criteria: (1) typical signs and symptoms of
meningitis (headache, temperature [38 C, nuchal rigidity,
and/or altered consciousness); (2) cerebrospinal fluid (CSF)
findings consistent with bacterial meningitis, including:
neutrophil (PMN) predominance, low glucose, high pro-
tein, high opening pressures, organisms on Gram stain, or
recovery of microorganisms from CSF or blood; (3) proof
of coexistent strongyloidiasis (larvae or eggs from any
specimens). Two cases in two patients were excluded
during this process.
In addition to the inclusion criteria, we collected the
following data: gender, age, outcome, symptoms, CSF
findings, S. stercoralis results, HIV testing results, medical/
social history, glucocorticoid use, colonoscopy results, and
use of antibiotics and antihelminthics.
We performed a Mann–Whitney U-test for CSF statis-
tical analysis and a one-sided Fisher’s exact test for out-
come statistical analysis, using Stata software (version
12.1; StataCorp, College Station, TX, USA).
Results
Thirty-three episodes in 21 patients were included in this
report. The median age at diagnosis was 58 years and
11/21 (52.4 %) patients were male.
Table 1 shows the gender, age, culture results for CSF
and blood, results of CSF Gram staining, serological results
for HTLV-1, specimens from which S. stercoralis was
detected, past history, initial antibiotics and antihelminthics
(antibiotics were subsequently chosen according to culture
results), and outcome of the patients. Six episodes of acute
meningitis without proven concurrent strongyloidiasis were
included because each of these patients had previous or
subsequent episodes of proven strongyloidiasis associated
with meningitis. Five of 21 patients (23.8 %) had more
than one episode of meningitis. Of these five patients, four
were treated with thiabendazole, and one was not treated
during the first episode because he was not diagnosed with
strongyloidiasis. Among the eight cases treated with iver-
mectin, none developed recurrent episodes of either
strongyloidiasis or meningitis.
Table 2 summarizes the culture results for CSF and
blood. K. pneumoniae was the most frequent pathogen,
followed by Streptococcus bovis (S. bovis) and E. coli. No
organism was isolated from CSF or blood cultures in 14/33
(42.4 %) episodes. Among culture-negative cases, only
patient 20 was prescribed antibiotics prior to lumbar
puncture. Gram-positive cocci (GPC) were detected in CSF
and/or blood cultures in 9/33 (27.3 %) episodes.
Serology for HTLV-1 was positive in 16/21 (76.2 %)
patients, including two cases of acute ATLL and four cases
with smoldering ATLL. Among five cases without HTLV-
1, two had previous neurosurgeries, two were diagnosed
with malnutrition, and one received glucocorticoid for
uveitis. Three patients had negative HIV test results
(patients 6, 13, and 17), but no other patients were exam-
ined for HIV due to the low prevalence in Japan.
Twenty-seven of 33 cases (81.8 %) improved without
neurological complications and 6/33 episodes (18.2 %)
ended in fatalities. Two patients simultaneously developed
acute ATLL. Among nine cases of GPC meningitis, only
patient 21 received three doses of dexamethasone, 0.15 mg/
kg every 8 h, which was discontinued after strongyloidiasis
was diagnosed. All patients with GPC meningitis recovered
without neurological complications, except for patient 20,
who developed acute ATLL and died. There was no sig-
nificant difference in outcome between culture-positive
cases and culture-negative cases. Fatal cases comprised 4/19
(21.0 %) in culture-positive cases and 2/14 (14.2 %) in
culture-negative cases (p-value 0.490).
Among 33 episodes of meningitis, fever was seen in 31
(93.9 %), headache in 30 (90.9 %), nausea and vomiting in
27 (81.8 %), rigors in 17 (51.5 %), and altered mental
status in 15 (45.5 %).
S. stercoralis was detected in the stool in 26/33 (78.8 %)
episodes, in gastric juice in 10/33 (30.3 %) episodes, in
sputum in 5/33 (12.1 %) episodes, and in ascites in 1/33
(3.0 %) episodes. S. stercoralis was detected only in the GI
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tract specimens in 23/33 (69.7 %) cases. Only two patients
underwent colonoscopy; patient 13 had diverticulosis and
patient 21 had benign adenoma, both of whom had S. bovis
meningitis. Nineteen of 21 (90.5 %) patients, including one
patient with previously resected colon cancer, did not
undergo colonoscopy.
Medians and interquartile ranges of CSF cell count,
PMN percentage, sugar, CSF/blood sugar ratio, and protein
were 1,440/mm3 (540–2,500), 84 % (71–96), 48 mg/dl
(25–64), 39 % (12–53), and 117 mg/dl (84–237), respec-
tively. There were no significant differences between cul-
ture-positive and culture-negative cases.
Table 1 Clinical features of all episodes
Patient Sex Age 
(yeara)
CSF culture Blood culture CSF Gram 
staining
HTLV-1 Specimens from which    
S. stercoralis was detected
Past history Antibiotics Antihelminthics Outcome
1 Female 75 (1990) (–) (–) PMN (+) Stool, sputum Smoldering ATLL ABPC, CTX Thiabendazole Recovery
2 Male 66 (1990) (–) S. bovis GPC (+) Stool None ABPC, CTX Thiabendazole Recovery
3 Female 61 (1990) Enterococcus sp (–) PMN (–) Stool, gastric juice Neurosurgery CTX Thiabendazole Recovery
4 Female 69 (1991) (–) (–) PMN (–) Stool Neurosurgery None Thiabendazole Recovery
5 Female 31 (1991) E. coli (–) PMN (+) Stool, gastric juice Meningitis
Strongyloidiasis
ABPC, CTX Thiabendazole Recovery
38 (1998) L. lactis L. lactis GNR Stool ABPC, CTX Thiabendazole Recovery
40 (2000) S. bovis S. bovis GPC Stool ABPC, CTX, VCM Thiabendazole Recovery
6 Female 29 (1992) K. pneumoniae K. pneumoniae PMN (+) Stool, gastric juice None CTX Thiabendazole Recovery
7 Male 38 (1992) S. sanguinis (–) PMN (+) Stool Strongyloidiasis
Chronic hepatitis B
ABPC, CTX Thiabendazole Recovery
43 (1997) (–) (–) GPC Stool CTX, VCM Thiabendazole Recovery
45 (1999) (–) (–) PMN Stool CTX Thiabendazole Recovery
45 (1999) (–) (–) PMN None CTX Thiabendazole Recovery
46 (2000) (–) (–) PMN Stool CTX Thiabendazole Recovery
49 (2003) (–) (–) PMN Stool, sputum CTX Ivermectin Recovery
8 Female 62 (1993) (–) E. coli PMN (+) Stool Meningitis
Strongyloidiasis
CTX Thiabendazole Recovery
63 (1993) E. coli E. coli PMN (+) None CTX Thiabendazole Recovery
64 (1995) (–) (–) PMN (+) None ABPC, CTX Thiabendazole Recovery
65 (1995) (–) E. coli PMN (+) None CTX Thiabendazole Recovery
9 Male 76 (1996) (–) K. pneumoniae PMN (+) Stool, gastric juice Smoldering ATLL ABPC, CTX Thiabendazole Recovery
76 (1996) K. pneumoniae K. pneumoniae GNR (+) None CTX Thiabendazole Death
10 Male 68 (1997) (–) (–) PMN (+) Stool, gastric juice Acute ATLL ABPC, CTX Thiabendazole Death
11 Male 60 (1997) (–) (–) PMN (+) Stool Smoldering ATLL ABPC, CTX Thiabendazole Recovery
12 Male 44 (1999) S. bovis S. bovis PMN (+) Stool Smoldering ATLL
Resected rectal CA
ABPC, CTX Thiabendazole Recovery
13 Male 66 (2002) S. bovis S. bovis GPC (+) Stool None ABPC, CTX Thiabendazole Recovery
14 Female 66 (2003) (–) (–) PMN (+) Stool RA, DM CTX, VCM Thiabendazole Recovery
15 Female 52 (2004) K. pneumoniae K. pneumoniae GNR (–) Stool, gastric juice, sputum Uveitisb, DM CTX Ivermectin Death
16 Female 81 (2004) (–) (–) PMN (–) Stool, gastric juice, sputum, 
ascites
Malnutrition CTX Ivermectin Death
17 Male 64 (2005) K. pneumoniae K. pneumoniae GNR (+) Gastric juice, sputum Malnutrition ABPC, CTX Ivermectin Recovery
18 Male 58 (2005) K. pneumoniae K. pneumoniae GNR (–) Gastric juice Malnutrition ABPC, CTX Ivermectin Death
19 Female 54 (2006) (–) (–) GNR (+) Stool Malnutrition CTX Ivermectin Recovery
20 Male 46 (2006) S. bovis S. bovis
K. pneumoniae
GPC (+) Stool, gastric juice Acute ATLL CTX, VCM Ivermectin Death
21 Male 49 (2009) (–) (–) PMN (+) Not performed None ABPC, CTX None Recovery
49 (2009) S. bovis (–) GPC (+) Stool ABPC, CTRX, VCM Ivermectin Recovery
ABPC ampicillin, ATLL adult T cell leukemia/lymphoma, CA carcinoma, CTRX ceftriaxone, CTX cefotaxime, DM diabetes mellitus, E. coli
Escherichia coli, GNR Gram-negative rods, GPC Gram-positive cocci, K. pneumoniae Klebsiella pneumoniae, L. lactic Lactococcus lactis, PMN
polymorphic nuclear neutrophils, RA rheumatoid arthritis, S. bovis Streptococcus bovis, S. sanguinis Streptococcus sanguinis, VCM vancomycin
a Indicates the year when diagnosis was made
b Oral glucocorticoid was prescribed
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Discussion
We present a series of 21 patients with neutrophil-domi-
nant meningitis associated with strongyloidiasis, including
14 cases with negative CSF and blood cultures. S. bovis
was the etiology for six patients, all of whom were positive
for HTLV-1. The following important points emerged from
our observations.
S. bovis is a GPC in the gut flora of 10–16 % of healthy
individuals [6]. It may cause bacteremia, endocarditis, and
meningitis in patients with GI lesions or colon cancer, and in
neonates [7, 8]. S. bovis has been reported as a rare cause of
bacterial meningitis associated with strongyloidiasis. Only
four cases of bacterial meningitis due to S. bovis have been
reported with strongyloidiasis; three had defective cellular
immunity (two with HIV and one due to steroids) and one was
reportedly immunocompetent [6, 9–11]. We detected six cases
in a single center over 20 years, which suggests that the inci-
dence of S. bovis meningitis in patients with strongyloidiasis
may be higher than previously suspected. This interaction
could impact the management of meningitis in geographic
areas where HTLV-1 and strongyloidiasis are endemic.
The Practice Guidelines for the Management of Bacte-
rial Meningitis published by the Infectious Diseases Soci-
ety of America (IDSA) recommend dexamethasone for
adults with suspected pneumococcal meningitis, with
dosage continued if the CSF Gram stain shows Gram-
positive diplococci [12]. This approach risks exacerbating
strongyloidiasis in cases of meningitis due to GPC asso-
ciated with strongyloidiasis, which cannot be reliably dis-
tinguished from pneumococci on Gram stain.
Glucocorticoid use is the strongest known risk factor for
disseminated strongyloidiasis, due to the acquired defect in
cell-mediated immunity. Glucocorticoids may act as ec-
dysteroids that accelerate the conversion of larvae from the
rhabditiform state to the invasive filariform state [1, 13].
One case of DS was reported after only a single dose of
dexamethasone prior to stereotactic radiosurgery [14].
Distinguishing pneumococcal meningitis from meningitis
due to other GPC on clinical grounds or Gram stain alone is
problematic. A modified approach to corticosteroid use in
GPC meningitis would, therefore, be advisable in areas
where strongyloidiasis is endemic. Patients with non-
pneumococcal meningitis do not benefit from steroids,
which are given to mitigate the harmful CSF inflammatory
response. Patients with underlying immunologic diseases
are less likely to mount self-damaging inflammatory
responses. The good clinical outcomes seen in our cases,
which were managed without glucocorticoids, may be
attributable to these factors. A comprehensive microbiol-
ogy approach using expanded techniques such as rapid
latex agglutination testing may be helpful for the early
identification of patients that can safely receive glucocor-
ticoids, if this testing is locally available [12].
Of our cases, 42.4 % had negative cultures of both blood
and CSF despite clinical meningitis and CSF pleocytosis,
which were clinically indistinguishable from culture-positive
cases. The postulated mechanism by which strongyloidiasis
causes bacteremia and meningitis is that parasitic ulceration/
perforations of the intestinal mucosa create a portal of entry
for enteric bacteria to reach the bloodstream. Mantovani et al.
[15] suggested that the bacteria are co-transported with the
migrating parasites. Kishaba et al. [16] proposed an entity of
‘‘culture-negative suppurative meningitis’’ associated with
DS. This hypothesis assumes that the parasite invades the
meninges without any attending bacteria, and that S.
stercoralis alone induces the intense inflammatory changes
that mimic the CSF findings of bacterial meningitis. Given
that the sensitivity of CSF or blood cultures in patients with
bacterial meningitis is reportedly [70 % [17–19], our fre-
quent observation of culture-negative suppurative meningitis
lends support to this hypothesis.
Among 14 patients treated with thiabendazole for
S. stercoralis, four (28.6 %) developed recurrence after
treatment; no patient treated with ivermectin relapsed.
These facts suggest that ivermectin may eradicate
S. stercoralis more effectively than thiabendazole, in which
case ivermectin should be considered for patients with
underlying immunodeficiency or associated meningitis.
The fact that S. stercoralis was detected only in GI tract
specimens in 69.7 % of cases supports the previously
suggested theory that localized strongyloidiasis can cause
enteric meningitis [2].
Limitations of this retrospective report of a single-center
experience include the low percentage of cases in which
colonoscopy excluded an additional portal of entry, such as
structural lesions/cancers, and the infrequency of HIV
testing. However, during the long-term follow-up of our
geographically restricted cases, neither colon cancer nor
HIV was diagnosed in any patient. Another limitation is a
Table 2 Summary of culture results
Organism CSF culture (%) Blood culture (%)
K. pneumoniae 5 (15.2) 7 (21.2)
S. bovis 5 (15.2) 5 (15.2)
E. coli 2 (6.1) 3 (9.1)
L. lactis 1 (3.0) 1 (3.0)
Enterococcus spp. 1 (3.0) 0
S. sanguinis 1 (3.0) 0
Negative 18 (54.5) 18 (54.5)
One case of mixed infection with K. pneumoniae and S. bovis is
included in the blood culture results
K. pneumoniae Klebsiella pneumoniae, S. bovis Streptococcus bovis,
E. coli Escherichia coli, L. lactis Lactococcus lactis, S. sanguinis
Streptococcus sanguinis
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lack of information regarding the S. bovis speciation
(Streptococcus gallolyticus or Streptococcus infantarius).
Further observation of the association between these three
infectious entities in additional institutions and other geo-
graphical areas will help establish the generalizability and
importance of these observations.
Conclusion
In areas where strongyloidiasis and human T-lymphotropic
virus-1 (HTLV-1) are endemic, clinical meningitis is sur-
prisingly common and frequently recurrent. Culture-nega-
tive meningitis and Streptococcus bovis meningitis may
represent a larger proportion of cases than the meningitis
seen in non-tropical areas. Clinicians should be aware that
these cases may represent a special scenario in which the
conventional use of glucocorticoids can pose a previously
unrecognized hazard. Further study is needed in order to
clarify the mechanisms by which these infections interact,
and to define the prevalence and significance of accom-
panying structural colonic lesions.
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